The impact of inter-cycle treatment delays on 5-year all-cause mortality in early-stage breast cancer: A retrospective cohort study
Authors:
Open Access
- 25 August 2024
- journal article
- research article
- Published by Elsevier in European Journal of Cancer
- Vol. 210, 114301
Abstract
No abstract availableKeywords
Funding Information
- National Institute for Health Research
This publication has 44 references indexed in Scilit:
- Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology)Breast Cancer Research and Treatment, 2022
- Evidence to guide the optimal timing for pre‐chemotherapy blood tests for early breast, colorectal cancer and diffuse large B‐cell lymphomaCancer Medicine, 2021
- Association of relative dose intensity with BMI and pathologic complete response in patients treated with neoadjuvant chemotherapy for breast cancerBreast Cancer Research and Treatment, 2020
- Impact of delayed treatment in women diagnosed with breast cancer: A population‐based studyCancer Medicine, 2020
- Relative dose intensity of first-line chemotherapy and overall survival in patients with advanced non-small-cell lung cancerSupportive Care in Cancer, 2019
- Impact of chemotherapy relative dose intensity on cause-specific and overall survival for stage I–III breast cancer: ER+/PR+, HER2- vs. triple-negativeBreast Cancer Research and Treatment, 2018
- Delayed Initiation of Adjuvant Chemotherapy Among Patients With Breast CancerJAMA Oncology, 2016
- Reducing febrile neutropenia rates in early breast cancer. Experience of two UK cancer centresSupportive Care in Cancer, 2014
- Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patientsBreast Cancer Research and Treatment, 2008
- Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapyBreast Cancer Research and Treatment, 2006